<analysis>
**Context this month.** October brings a Claude successor launch, which will compete for compute and checkpoints. It also carries the non-binding 45-day review, due around 13 November, and the judge asked that review to bite. The V5 misuse thread stays live: I carry about a 20–25% chance per month of a confirmed notable incident using a V5 fine-tune, resolved as an exogenous event and not tied to any action.

**Action 1 (history-blind reconstruction comparison).**
- The action accepts an explicit negative result as a deliverable, so the realistic failure mode is not running an adequately powered comparison at all, rather than getting a bad answer.
- Blockers:
  - Contention from the October successor launch. The Q4 reservation helps but does not fully protect.
  - Staff reviewers are thin.
  - Freezing the power analysis by 7 October is fast but internal.
- Loss of the DeepSeek arm is modelled by Threat 1, and handoff under-acceptance by Threat 2. Neither is counted again here.
- Modest execution risk.

**Action 2 (portable multi-arm training bet).**
- This is very ambitious for 31 days:
  - three matched training arms;
  - persistence after further capability training;
  - a second round of agent-generated data;
  - Apollo contracting;
  - a reserved successor slot;
  - a published recipe by 24 October.
- Publication has slipped every time. Past examples: the 19 August release was held past earnings, and pre-clearance ran to 25 September. A recipe clearing GC within about three weeks is unlikely.
- The Apollo contract is the easy piece.
- The DeepSeek-specific block belongs to Threat 1. Even without it, the Claude arm plus publication is likely to fall short.
- High failure risk.

**Action 3 (defensive V5 release).**
- The security channel has the best track record: merged patches, the Qwen retest, and a CISA citation.
- Repairing 40% of the tests and getting one maintained release merged in a month with maintainers who already cooperate is plausible.
- The consequential-workflow proposal only needs to be prepared, not activated.
- Ohio's committee decision and the insurer response are outside the player's control, but the action asks only to deliver materials.
- Moderate-low risk.

**Action 4 (households and 1,500 outputs).**
- The casework and B packet have worked when ring-fenced.
- 1,500 outputs from a beta that produced about 260 needs the résumé flow extended to the full beta, plus distribution. Routing across instances is modelled by Threat 4.
- The bridge request has a precedent ($10.4K was approved).
- Moderate risk.

**Action 5 (evaluator rider and sponsor).**
- Getting the rider approved means GC, enterprise counsel, a named evaluator, customer consent, and a leadership decision, all within two weeks.
- The GC mechanism belongs to Threat 3. Even so, customer consent to production testing during AI-exclusion renewal, and a sponsor disposition before the CR fight, are real independent headwinds.
- Moderate-high risk.

**Threats.**
- **Threat 1.** Anthropic's own distillation accusations and §1532 exposure make a legal and security review highly likely. The isolated reconstructor arm is somewhat less exposed than training plus publication.
- **Threat 2.** The trade of false passes for false rejections is a well-known verifier dynamic, and the handoff slice is structurally hard.
- **Threat 3.** GC has stalled three policy products in a row.
- **Threat 4.** Changing default behaviour needs product and Trust & Safety sign-off, and product growth has refused twice.
- **Threat 5.** GPT-6.2 only just shipped, and Gemini 4.5 went to GA in July. A major rival announcement in October is possible but not the base case.
</analysis>

<action_odds>
Action 1 [history-blind reconstruction comparison]: P(failure) 35%. Reason: the comparison can be run with existing checkpoints and staff, and a negative result is an acceptable deliverable. Launch contention and review-hour scarcity are the main execution risks. The DeepSeek and handoff risks are carried by Threats 1 and 2.

Action 2 [portable multi-arm training + recipe]: P(failure) 60%. Reason: there are too many components for one month. Publication-clearance lag has made every prior release slip, and there is launch compute contention. Only the Apollo contract and a partial Claude arm are likely. The DeepSeek-specific block is excluded here and left to Threat 1.

Action 3 [defensive V5 release]: P(failure) 30%. Reason: it runs through the strongest existing channel with maintainers who already cooperate. Repairing 40% of the tests plus adversarial coverage in a month is feasible, though the merge could slip past 31 October.

Action 4 [households + 1,500 outputs]: P(failure) 40%. Reason: the casework and B packet are well established. The output target is about 6× last month's and depends on extending the flow to the full beta. The routing risk is carried by Threat 4.

Action 5 [evaluator rider + sponsor]: P(failure) 50%. Reason: two weeks is short for a named evaluator, customer consent during AI-exclusion renewal, and a leadership pilot decision. There is congressional bandwidth pressure ahead of the CR. The GC-specific stall is carried by Threat 3.
</action_odds>

<threat_odds>
Threat 1 [DeepSeek arms blocked]: P(materialises) 55%. Adversary suggested 50%. I set it slightly higher because Anthropic's own public distillation accusations, its §1532 government exposure, and the optics of improving DeepSeek make a mandatory review very likely. The leak sub-case would be a smaller part of the outcome.

Threat 2 [blind reconstructors reject handoffs]: P(materialises) 45%. Adversary suggested 40%. I set it slightly higher because the handoff slice is exactly where September failed, and removing history plausibly trades false passes for false rejections.

Threat 3 [rider stalls at GC/customer counsel]: P(materialises) 60%. Adversary suggested 55%. I set it slightly higher because GC is three for three on holding or rewriting policy products, and this rider hits the same enterprise-terms conflict that held the purchasing template.

Threat 4 [default routing not authorised]: P(materialises) 50%. Adversary suggested 50%. I match it: product has refused twice and a behaviour change needs Trust & Safety and privacy review, but the action frames routing as responding to user requests, which lowers the bar somewhat.

Threat 5 [rival automation jump]: P(materialises) 30%. Adversary suggested 35%. I set it slightly lower because GPT-6.2 only just shipped and Gemini 4.5 is recent, so a major new announcement within October is possible but below even odds. Measurable erosion of the Q4 allocation would come mostly at the November review, not in October.
</threat_odds>
